Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines

Biochemical Pharmacology

Volumn 58, Issue 7, 1999, Pages 1097-1107

  Lim, Jin T E ^a   Piazza, Gary A ^a   Han, Edward Kyu Ho ^a   Delohery, Thomas M ^b   Li, Han ^a   Finn, Tyler S ^a   Buttyan, Ralph ^a   Yamamoto, Hirofumi ^a   Sperl, Gerhard J ^a   Brendel, Klaus ^a   Gross, Paul H ^a   Pamukcu, Rifat ^a   Weinstein, I Bernard ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b Cell Pathways Inc   (United States)

Author keywords

Apoptosis; bcl 2; Cyclooxygenase; Nonsteroidal anti inflammatory drug; Prostate cancer; Sulindac

Indexed keywords

CP 248; NONSTEROID ANTIINFLAMMATORY AGENT; PREVATEC; PROSTAGLANDIN SYNTHASE; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM;

ANDROGENS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CYCLOOXYGENASE INHIBITORS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULINDAC; TUMOR CELLS, CULTURED;

EID: 0033213814     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00200-2     Document Type: Article

References (50)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics, 1996. CA Cancer J Clin. 46:1996;5-27.
2. Raffo A.J., Perlman H., Chen M.-W., Day M.L., Streitman J.S., Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 55:1995;4438-4445.
3. Kyrianou N. Apoptosis Therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer . World J Urol. 12:1994;299-303.
4. Bauer J.J., Sesterhenn I.A., Mostofi F.K., McLeod D.G., Srivastava S., Moul J.W. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 156:1996;1511-1516.
5. Theodorescu D., Broder S.R., Boyd J.C., Mills S.E., Frierson H.F.F. Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol. 158:1997;131-137.
6. Waddell W.R., Gerner R.E., Reich M.P. Nonsteroidal antiinflammatory drugs and tamoxifen for desmoid tumours and carcinoma of the stomach. J Surg Oncol. 22:1983;197-211.
7. Waddell W.R., Loughry R.W. Sulindac for polyposis of the colon. J Surg Oncol. 24:1983;83-87.
8. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., Offerhaus G.J.A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 328:1993;1313-1316.
9. Moorghen M., Ince P., Finney K.J., Sunter J.O., Appleton D.R., Watson A.J. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol. 156:1988;341-347.
10. Beazer-Barclay Y., Levy D.B., Moser A.R., Dove W.F., Hamilton S.R., Vogelstein B., Kinzler K.W. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis. 17:1996;1757-1760.
11. Nugent K.P., Farmer K.C., Spigelman A.D., Williams C.D., Phillips K.R. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 80:1993;1618-1619.
12. Pasricha P.J., Bedi A., O'Connor K., Rashid A., Akhtar A.J., Zahurak L.M., Piantadosi S., Hamilton S.R., Giardiello R.M. The effect of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology. 109:1995;994-998.
13. Piazza G.A., Rahm A.L., Krutzsch M., Sperl G., Paranka N.S., Gross P.H., Brendel K., Burt R.W., Alberts D.S., Pamukcu R. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 55:1995;3110-3116.
14. Piazza G.A., Rahm A.K., Finn T.S., Fryer B.H., Li H., Stoumen A.L., Pamukcu R., Ahnen D.J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 57:1997;2452-2459.
15. Elder D.J.E., Halton D.E., Hague A., Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug Independence from COX-2 protein expression . Clin Cancer Res. 3:1997;1679-1683.
16. Hanif R., Pittas A., Feng Y., Koutsos M.I., Qiao L., Staiano-Coico L., Shiff S.I., Rigas B. Effects of non-steroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol. 52:1996;237-245.
17. Arber N., Han E.K.-H., Sgambato A., Piazza G.A., Delohery T.M., Begemann M., Weghorst C.M., Kim N.-H., Pamukcu R., Ahnen D.J., Reed J.C., Weinstein I.B. A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes. Gastroenterology. 113:1997;1892-1900.
18. Thompson H.J., Briggs S., Paranka N.S., Piazza G.A., Brendel K., Gross P.H., Sperl G.J., Pamukcu R., Ahnen D.J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst. 87:1995;1259-1260.
19. Thompson H.J., Jiang C., Lu J., Menta R.G., Piazza G.A., Paranka N.S., Pamukcu R., Ahnen D.J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 57:1997;1-6.
20. Han E.K.-H., Arber N., Yamamoto H., Lim J.T.E., Delohery T.M., Pamukcu R., Piazza G.A., Xing W.Q., Weinstein I.B. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat. 48:1998;195-203.
21. Piazza G.A., Alberts D.S., Hixson L.J., Paranka N.S., Li H., Finn T., Bogert C., Guillen J.M., Brendel K., Gross P.H., Sperl G., Ritchie J., Burt R.W., Ellsworth L., Ahnen D.J., Pamukcu R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57:1997;2909-2915.
22. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 43:1983;1809-1818.
23. Carruba G., Granata D.M., Farruggio R., Cannella S., Bue A.L., Leake R.E., Pavone-Macaluso M., Castagnetta L.A. Steroid-growth factor interaction in human prostate cancer. 2. Effects of transforming growth factors on androgen metabolism of prostate cancer cells. Steroids. 61:1996;41-46.
24. Hayward S.W., Dahiya R., Cunha G.R., Bartek J., Deshpande N., Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line BPH-1 . In Vitro Cell Dev Biol Anim. 31:1995;14-24.
25. Rajapaksa R., Ginzton N., Rott L.S., Greenberg P.L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood. 88:1997;4275-4287.
26. Datta R., Kojima H., Yoshida K., Kufe D. Caspase-3 mediated-cleavage of protein kinase Cθ in induction of apoptosis. J Biol Chem. 272:1997;20317-20320.
27. 2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res. 57:1997;2388-2393.
28. Boopathy R., Balasubramanian A.S. Purification and characterization of sheep platelet cyclo-oxygenase. Acetylation by aspirin prevents haemin binding to the enzyme. Biochem J. 239:1986;371-377.
29. Marin M.C., Hsu B., Meyn R.E., Donehower L.A., el-Naggar A.K., McDonnell T.J. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene. 9:1994;3107-3112.
30. Martin S.J., Newmeyer D.D., Mathias S., Farschon D.W., Wang H.G., Reed J.C., Kolesnick R.N., Green D.R. Cell-free reconstitution of Fas-, UV radiation- and ceramide-induced apoptosis. EMBO J. 14:1995;5191-5200.
31. Kitada S., Krajewski S., Miyashita T., Krajewska M., Reed J.C. γ-Radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo. Oncogene. 12:1996;187-192.
32. Strasser A., Anderson R.L. Bcl-2 and thermotolerance cooperate in cell survival. Cell Growth Differ. 6:1995;799-805.
33. Pittman R.N., Wang S., DiBeneditto A.J., Mills J.C. A system for characterizing cellular and molecular events in programmed neuronal cell death. J Neurosci. 13:1993;3669-3680.
34. 2 in breast carcinoma cells. Oncogene. 10:1995;2297-2305.
35. Kane D.J., Sarafian T.A., Anton R., Hahn H., Gralla E.B., Valentine J.S., Ord T., Bredesen D.E. Bcl-2 inhibition of neural death Decreased generation of reactive oxygen species . Science. 262:1993;1274-1277.
36. 2+ fluxes. Proc Natl Acad Sci USA. 91:1994;6569-6573.
37. 2+. Oncogene. 12:1996;2259-2266.
38. Miura M., Zhu H., Rotello R., Hartwieg E.A., Yuan J. Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell. 75:1993;653-660.
39. Marin M.C., Hsu B., Stephens L.C., Brisbay S., McDonnell T.J. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp Cell Res. 217:1995;240-247.
40. Miyashita T., Reed J.C. Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic agents. Cancer Res. 52:1992;5407-5411.
41. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255.
42. L gene expression. FEBS Lett. 407:1997;97-100.
43. Marnett L. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52:1992;5575-5589.
44. Meade E.A., Smith W.L., Dewitt D.L. Differential inhibition of prostaglandin endoperoxidase synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 268:1993;6610-6614.
45. Chan T.A., Morin P.J., Vogelstein B., Kinzler K.W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA. 95:1998;681-686.
46. Alberts D.S., Hixson L., Ahnen D., Bogert C., Einspahr J., Paranka N., Brendel K., Gross P.H., Pamukcu R., Burt R.W. Do NSAIDs exert their colon cancer chemopreventive activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem. 22:1995;18-23.
47. Planchon S.M., Wuerzberger S., Frydman B., Witiak D.T., Hutson P., Church D.R., Wilding G., Boothman D.A. β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells A p53-independent response . Cancer Res. 55:1995;3706-3711.
48. Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 23:1993;123-134.
49. Goldberg Y., Nassif I.I., Pittas A., Tsai L.-L., Dynlacht B.D., Rigas B., Shiff S.J. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells Alterations in tumor suppressor and cell cycle-regulatory proteins . Oncogene. 12:1996;893-901.
50. Goluboff E.T., Shabsigh A., Saidi J.A., Weinstein I.B., Mitra N., Heitjan D., Piazza G.A., Pamukcu R., Buttyan R., Olsson C.A. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology. 53:1999;440-445.